Table 2 Univariate and multivariate analysis for local control and overall survival according to patient and tumor characteristics ( ^§ primary treatment vs progression after pretreatment; &complete remission/stable disease vs progressive disease; *colorectal cancer vs. other; **volume and minimum biologically effective dose as continuous variables; ECOG performance status 0 vs. 1-2; abbreviations: GTV=gross tumor volume, PTV=planning target volume, PS= performance status, HR=hazard ratio, CI=95% confidence interval)

Indication for SBRT ^§

0.91 (0.42-1.99)

0.82

0.97 (0.35-2.72)

0.96

Prior CTx

0.66 (0.25-1.79)

0.42

0.33 (0.08-1.30)

0.11

Histology*

1.69 (0.72-3.98)

0.22

1.58 (0.61-4.10)

0.35

GTV Volume**

1.003 (1-1.005)

0.03

1.002 (0.99-1.004)

0.27

BED PTV**

0.95 (0.92-0.99)

0.01

0.98 (0.93-1.03)

0.38

BED GTV**

0.97 (0.96-0.99)

<0.001

0.98 (0.96-0.996)

0.015

Overall survival

Univariate

Multivariate

HR (CI)

p-value

HR (CI)

p-value

ECOG PS

0.71 (0.38-1.34)

0.29

0.92 (0.53-2.25)

0.83

Histology*

0.53 (0.29-0.98)

0.04

0.65 (0.32-1.34)

0.25

Prior CTx

0.58 (0.26-1.33)

0.19

0.70 (0.26-1.87)

0.47

Extrahepatic disease status before SBRT&

2.5 (1.3-4.8)

0.005

1.69 (0.81-3.51)

0.16

GTV Volume**

1.003 (1.001-1.004)

<0.001

1.003 (1.001-1.004)

0.002

Local recurrence after SBRT

0.80 (0.42-1.52)

0.5

0.70 (0.34-1.48)

0.35